Cellectar Biosciences Inc Dossier - Source-backed chat

Cellectar Biosciences Inc

CLRBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.70

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.87Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $17.7M

Enterprise Value −$14.7M

Shares Outstanding 9.3M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cellectar Biosciences is a late-stage clinical biopharmaceutical company poised for a transformative transition from R&D to commercial operations. The investment thesis centers on its lead radiotherapeutic candidate, iopofosine I 131, which has demonstrated exceptional efficacy and durability in a Phase 2b pivotal trial (CLOVER WaM) for relapsed/refractory Waldenström Macroglobulinemia (WM). With mature 12-month follow-up data meeting FDA expectations, a clear regulatory pathway for accelerated approval in the U.S., and a planned EMA Conditional Marketing Authorization filing in 3Q 2026, the regulatory risk is significantly mitigated. Furthermore, a major $140 million financing completed in May 2026 provides the necessary capital runway into Q2 2027, supporting both the NDA filing and the initiation of a Phase 3 confirmatory trial. While the company remains pre-revenue and highly speculative, the high unmet medical need in post-BTKi WM patients and the platform potential of its Phospholipid Drug Conjugate (PDC) technology present substantial asymmetric upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$11.50

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.2015%

The bear case is triggered by regulatory delays, such as the FDA requesting additional clinical data or raising manufacturing/CMC concerns, which pushes back the approval timeline beyond 2027. This delay would exhaust the company's cash runway, forcing highly dilutive equity raises or unfavorable debt financing. Additionally, if the Phase 3 confirmatory trial experiences slow enrollment or safety signals emerge in the CLR 125 solid tumor trials, investor confidence in the PDC platform would be severely damaged.

Base CaseCentral scenario

$10.0060%

The base case assumes Cellectar successfully files for EMA Conditional Marketing Approval in 3Q 2026 and submits its U.S. NDA for accelerated approval in late 2026 or early 2027. The Phase 3 confirmatory trial initiates on schedule in 4Q 2026. The stock's valuation is driven by the high probability of approval in WM, where there are currently no FDA-approved therapies for patients progressing on BTKi therapy. The cash runway is managed prudently to sustain operations through the regulatory review period.

Bull CaseUpside scenario

$11.5525%

The bull case assumes rapid FDA accelerated approval and EMA conditional marketing approval for iopofosine I 131 in WM by early 2027, leading to a highly successful commercial launch. In this scenario, iopofosine quickly establishes itself as the standard of care for post-BTKi WM patients due to its fixed-duration dosing and high major response rates. Additionally, early clinical readouts from the CLR 125 Auger-emitting program in solid tumors (TNBC) and the CLR 225 alpha-emitting program demonstrate strong platform validation, attracting a lucrative global co-development partnership with a major pharmaceutical firm.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Compelling clinical efficacy of iopofosine I 131 in r/r WM, achieving a 61.8% Major Response Rate and 17.8-month median Duration of Response in a heavily pretreated population.
Clear regulatory pathway with FDA Breakthrough Therapy and traditional accelerated approval pathway confirmed, alongside mature 12-month follow-up data in hand.
Substantial market opportunity in the post-BTKi setting where no FDA-approved salvage therapies exist, offering a novel mechanism of action and time-limited treatment.
Strong institutional backing and capital runway secured through a $140 million oversubscribed financing in May 2026, funding operations into Q2 2027.
Broad platform optionality with the proprietary Phospholipid Drug Conjugate (PDC) technology, enabling targeted delivery of beta, alpha, and Auger-emitting payloads.

Key Investment Risks

Pre-revenue biopharmaceutical risk with ongoing net losses ($5.7 million in Q1 2026) and high cash burn from clinical development.
Regulatory approval risk, as any delay or Refusal to File from the FDA or EMA would severely impact the commercialization timeline and valuation.
Execution and enrollment risk associated with the upcoming Phase 3 confirmatory trial in WM, which must be completed post-accelerated approval.
Potential dilution from a significant warrant overhang, with millions of milestone-based warrants outstanding from the May 2026 financing.
Commercial adoption risk in a competitive oncology landscape, requiring the build-out of specialized radiopharmaceutical distribution and sales capabilities.

Thesis Invalidation Triggers

A Refusal to File or Complete Response Letter (CRL) from the FDA regarding the iopofosine I 131 NDA.
Failure to initiate the Phase 3 confirmatory trial for iopofosine I 131 in WM by the end of 2026.
Severe, unexpected safety signals or toxicities emerging in the CLR 125 Phase 1b trial or the iopofosine clinical program.
Inability to maintain compliance with Nasdaq's continued listing standards, leading to delisting threats.
Inability to secure additional non-dilutive funding or strategic partnerships if the cash runway is depleted faster than projected.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.